Sign Up
OverviewAPI
Beyond Air, Inc. reports its Q3 financial results with revenues of $0.4 million and a net loss of $16.2 million. The company focuses on harnessing nitric oxide for medical applications, including FDA approval for LungFit PH for neonate treatment. Beyond Air is also advancing LungFit systems for lung infections and autism disorder treatment, while Beyond Cancer explores high nitric oxide concentrations for targeting solid tumors.

Ask a question